Recruiting

Anti-VEGF Therapies

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT05108519

Conditions

Hematopoietic and Lymphoid Cell Neoplasm

Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Electronic Health Record Review

Study Details

Brief summary:

This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies. This study aims to observe side effects that may happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This may help doctors learn if there are any relationships between these side effects and how the disease may respond to treatment.

Conditions

Hematopoietic and Lymphoid Cell Neoplasm

Malignant Solid Neoplasm

Study ID

NCT05108519

Start date

Apr 8, 2019

Status verified date

Aug, 2026

Completion date

Feb 2, 2027

Anticipated

Primary completion date

Feb 2, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients must be able to understand and be willing to sign a written informed consent document
  • Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy

Study Design

Enrollment

170 participants

Anticipated

Interventions and Outcome Measures

Arms

Observational (medical records review)

Patients' medical records are reviewed.

Interventions

Electronic Health Record Review

Medical records are reviewed

Primary outcome measure

  • Incidence of grade 3+ adverse events (AE) at least possibly related to anti-VEGF-related treatment (overall and each type separately) [ Time Frame: Up to 5 years ]

Central Contacts and Locations

Locations

M D Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Nicolas L. Palaskas

713-563-3532nlpalaskas@mdanderson.org

Principal Investigator:

Nicolas L. Palaskas

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Aug 10, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-08-10.